These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 25631614)

  • 1. Depressive symptoms accelerate cognitive decline in amyloid-positive MCI patients.
    Brendel M; Pogarell O; Xiong G; Delker A; Bartenstein P; Rominger A;
    Eur J Nucl Med Mol Imaging; 2015 Apr; 42(5):716-24. PubMed ID: 25631614
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dissociation between brain amyloid deposition and metabolism in early mild cognitive impairment.
    Wu L; Rowley J; Mohades S; Leuzy A; Dauar MT; Shin M; Fonov V; Jia J; Gauthier S; Rosa-Neto P;
    PLoS One; 2012; 7(10):e47905. PubMed ID: 23112868
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serotonin Selective Reuptake Inhibitor Treatment Improves Cognition and Grey Matter Atrophy but not Amyloid Burden During Two-Year Follow-Up in Mild Cognitive Impairment and Alzheimer's Disease Patients with Depressive Symptoms.
    Brendel M; Sauerbeck J; Greven S; Kotz S; Scheiwein F; Blautzik J; Delker A; Pogarell O; Ishii K; Bartenstein P; Rominger A;
    J Alzheimers Dis; 2018; 65(3):793-806. PubMed ID: 30010116
    [TBL] [Abstract][Full Text] [Related]  

  • 4. White matter lesion load is associated with resting state functional MRI activity and amyloid PET but not FDG in mild cognitive impairment and early Alzheimer's disease patients.
    Zhou Y; Yu F; Duong TQ;
    J Magn Reson Imaging; 2015 Jan; 41(1):102-9. PubMed ID: 24382798
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diagnosed mild cognitive impairment due to Alzheimer's disease with PET biomarkers of beta amyloid and neuronal dysfunction.
    Hatashita S; Yamasaki H
    PLoS One; 2013; 8(6):e66877. PubMed ID: 23799136
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Principal-Component Analysis-Based Measures of PET Data Closely Reflect Neuropathologic Staging Schemes.
    Blazhenets G; Frings L; Sörensen A; Meyer PT;
    J Nucl Med; 2021 Jun; 62(6):855-860. PubMed ID: 33097630
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relationship Between Body Mass Index, ApoE4 Status, and PET-Based Amyloid and Neurodegeneration Markers in Amyloid-Positive Subjects with Normal Cognition or Mild Cognitive Impairment.
    Blautzik J; Kotz S; Brendel M; Sauerbeck J; Vettermann F; Winter Y; Bartenstein P; Ishii K; Rominger A;
    J Alzheimers Dis; 2018; 65(3):781-791. PubMed ID: 28697560
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discriminative Power of Arterial Spin Labeling Magnetic Resonance Imaging and 18F-Fluorodeoxyglucose Positron Emission Tomography Changes for Amyloid-β-Positive Subjects in the Alzheimer's Disease Continuum.
    Tosun D; Schuff N; Jagust W; Weiner MW;
    Neurodegener Dis; 2016; 16(1-2):87-94. PubMed ID: 26560336
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of brain amyloidosis with the incidence and frequency of neuropsychiatric symptoms in ADNI: a multisite observational cohort study.
    Goukasian N; Hwang KS; Romero T; Grotts J; Do TM; Groh JR; Bateman DR; Apostolova LG
    BMJ Open; 2019 Dec; 9(12):e031947. PubMed ID: 31857304
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Left lateralized cerebral glucose metabolism declines in amyloid-β positive persons with mild cognitive impairment.
    Weise CM; Chen K; Chen Y; Kuang X; Savage CR; Reiman EM;
    Neuroimage Clin; 2018; 20():286-296. PubMed ID: 30101060
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Joint Assessment of Quantitative 18F-Florbetapir and 18F-FDG Regional Uptake Using Baseline Data from the ADNI.
    Ben Bouallègue F; Mariano-Goulart D; Payoux P;
    J Alzheimers Dis; 2018; 62(1):399-408. PubMed ID: 29439345
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Correlation Between Brain 18F-AV45 and 18F-FDG PET Distribution Characteristics and Cognitive Function in Patients with Mild and Moderate Alzheimer's Disease.
    Jing J; Zhang F; Zhao L; Xie J; Chen J; Zhong R; Zhang Y; Dong C
    J Alzheimers Dis; 2021; 79(3):1317-1325. PubMed ID: 33427748
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cortical Amyloid β Deposition and Current Depressive Symptoms in Alzheimer Disease and Mild Cognitive Impairment.
    Chung JK; Plitman E; Nakajima S; Chakravarty MM; Caravaggio F; Gerretsen P; Iwata Y; Graff-Guerrero A;
    J Geriatr Psychiatry Neurol; 2016 May; 29(3):149-59. PubMed ID: 26400248
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of short-term cognitive decline and MCI-to-AD dementia conversion with CSF, MRI, amyloid- and
    Ottoy J; Niemantsverdriet E; Verhaeghe J; De Roeck E; Struyfs H; Somers C; Wyffels L; Ceyssens S; Van Mossevelde S; Van den Bossche T; Van Broeckhoven C; Ribbens A; Bjerke M; Stroobants S; Engelborghs S; Staelens S
    Neuroimage Clin; 2019; 22():101771. PubMed ID: 30927601
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alzheimer Disease Signature Neurodegeneration and APOE Genotype in Mild Cognitive Impairment With Suspected Non-Alzheimer Disease Pathophysiology.
    Schreiber S; Schreiber F; Lockhart SN; Horng A; Bejanin A; Landau SM; Jagust WJ;
    JAMA Neurol; 2017 Jun; 74(6):650-659. PubMed ID: 28319241
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Depressive Symptoms are Associated with Progression to Dementia in Patients with Amyloid-Positive Mild Cognitive Impairment.
    Moon B; Kim S; Park YH; Lim JS; Youn YC; Kim S; Jang JW;
    J Alzheimers Dis; 2017; 58(4):1255-1264. PubMed ID: 28550264
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Amyloid Burden and Depressive Symptom Trajectories in Older Adults at Risk of Developing Cognitive Decline.
    Conejero I; Dubois J; Gutierrez LA; Delrieu J; Arbus C; Garcia M; Lopez-Castroman J; Courtet P; Gabelle A
    J Clin Psychiatry; 2021 Aug; 82(5):. PubMed ID: 34352166
    [No Abstract]   [Full Text] [Related]  

  • 18. Early detection of amyloid load using
    Bullich S; Roé-Vellvé N; Marquié M; Landau SM; Barthel H; Villemagne VL; Sanabria Á; Tartari JP; Sotolongo-Grau O; Doré V; Koglin N; Müller A; Perrotin A; Jovalekic A; De Santi S; Tárraga L; Stephens AW; Rowe CC; Sabri O; Seibyl JP; Boada M
    Alzheimers Res Ther; 2021 Mar; 13(1):67. PubMed ID: 33773598
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Depressive symptoms in mild cognitive impairment predict greater atrophy in Alzheimer's disease-related regions.
    Lee GJ; Lu PH; Hua X; Lee S; Wu S; Nguyen K; Teng E; Leow AD; Jack CR; Toga AW; Weiner MW; Bartzokis G; Thompson PM;
    Biol Psychiatry; 2012 May; 71(9):814-21. PubMed ID: 22322105
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FDG-PET and CSF biomarker accuracy in prediction of conversion to different dementias in a large multicentre MCI cohort.
    Caminiti SP; Ballarini T; Sala A; Cerami C; Presotto L; Santangelo R; Fallanca F; Vanoli EG; Gianolli L; Iannaccone S; Magnani G; Perani D;
    Neuroimage Clin; 2018; 18():167-177. PubMed ID: 29387532
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.